 |
|
|
|
|
|
|
|
 |
 |
 |
 |
 |
 |
 |
|
Overview SelectX Pharmaceuticals, Inc. is rapidly establishing itself as a leader in the innovation and application of Genetic Chemistry for small molecule drug discovery. The Company focuses its discovery and development efforts on antimicrobial and other therapeutics that address unmet medical needs. SelectX's most advanced program is a preclinical aminoglycoside antibiotic that addresses the rapidly growing gram-negative hospital infection market. A second preclinical program, a novel carbapenem antibiotic, addresses the need for Pseudomonas coverage which is lacking in currently marketed beta-lactams and other broad spectrum antibiotics for serious infections. SelectX has developed a proprietary, robust Genetic Chemistry platform that is both central to its current antimicrobial discovery efforts and also broadly applicable to a wide variety of chemistries and indications. |
SelectX Pharmaceuticals, Inc. |